Results 51 to 60 of about 71,425 (202)

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

Nature Communications, 2021
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or proteomic features in involved tissues that define pathobiological differences between patients.
Bradley A. Maron, Rui-Sheng Wang, Sergei Shevtsov, Stavros G. Drakos, Elena Arons, Omar Wever-Pinzon, Gordon S. Huggins, Andriy O. Samokhin, William M. Oldham, Yasmine Aguib, Magdi H. Yacoub, Ethan J. Rowin, Barry J. Maron, Martin S. Maron, Joseph Loscalzo   +14 more
doaj   +1 more source

Apical Hypertrophic Cardiomyopathy: A Case Report

In this case report, a patient with apical hypertrophic cardiomyopathy (AHCM) who presented to the emergency department with chest pain is presented. The symptoms, clinical findings, diagnostic methods, differential diagnosis, and treatment options for ...
Duzgun Can Senbil, Ayse Sena Celik, Mutlu Buyuklu   +2 more
core   +1 more source

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy

, 2002
Background-Although studies have suggested that "late-onset" hypertrophic cardiomyopathy (HCM) may be caused by sarcomeric protein gene mutations, the cause of HCM in the majority of patients is unknown.
Tei, C, B. Sachdev, Takenaka, T, W. J. Mckenna, Sachdev, B, H. Teraguchi, Elliott, PM, Teraguchi, H, C. Tei, P. Lee, T. Takenaka, McKenna, WJ, Lee, P, Hypertrophic Cardiomyopathy   +13 more
core  

Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Dedicated hypertrophic cardiomyopathy (HCM) center cohorts have reported reductions in HCM‐related deaths, likely due to the introduction of contemporary treatments.
Ahmed Sayed, Barry J. Maron, Ethan J. Rowin, Martin S. Maron   +3 more
doaj   +1 more source

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

The clinical characteristics of families with hypertrophic cardiomyopathy associated with mutations of cardiac myosin binding protein C

, 2010
Introduction: Mutations in cardiac myosin binding protein-C (MYBPC3), the most common genetic cause of hypertrophic cardiomyopathy (HCM), have been reported to cause a comparatively benign and late-onset form of the disease with incomplete penetrance ...
Page, S.P.
core  

Identification of a novel titin-cap/telethonin mutation in a Portuguese family with hypertrophic cardiomyopathy

Revista Portuguesa de Cardiologia, 2020
Introduction and objectives: Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease; there is still a large proportion of patients with no identified disease-causing mutation.
Alexandra Toste, Andreas Perrot, Cemil Özcelik, Nuno Cardim   +3 more
doaj   +1 more source

Explainable artificial intelligence identifies and localizes left ventricular scar in hypertrophic cardiomyopathy using 12-Lead electrocardiogram

Scientific Reports
Left ventricular (LV) scar is a major risk factor for sudden death and heart failure in hypertrophic cardiomyopathy (HCM). LV scar evolves over time and needs longitudinal assessment. Currently, LV scar detection relies on late gadolinium enhancement MRI,
Kasra Nezamabadi, Sanjay Sivalokanathan, Jiwon Lee, Talha Tanriverdi, Meiling Chen, Daiyin Lu, Jadyn Abraham, Neda Sardaripour, Pengyuan Li, Parvin Mousavi, M. Roselle Abraham   +10 more
doaj   +1 more source

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

, 2020
Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction.
Jensen, Morten K, Bondue, Antoine, Afshar, Kia, Hegde, Sheila SM, Oreziak, Artur, Bhattacharya, Mondira, Solomon, Scott D., Wheeler, Matthew T., Waldman, Cynthia Burstein, Ho, Carolyn Y, Sehnert, Amy J., Solomon, Scott D, Kubanek, Milos, Garcia-Pavia, Pablo, Sehnert, Amy AJ, Zhang, David, Brunner-La Rocca, Hans peter; id_orcid, Wheeler, Matthew MT, Lakdawala, Neal K., Masri, Ahmad, Li, Wanying, Wang, Andrew, Abraham, Theodore P, Edelberg, Jay JM, Edelberg, Jay M., Saberi, Sara, Abraham, Theodore P., Brunner-La Rocca, Hans peter, Barriales-Villa, Roberto, Jacoby, Daniel, Lakdawala, Neal NK, Gimeno-Blanes, Juan, Myers, Jonathan, Lester, Steven J., Hegde, Sheila M., Lester, Steven J, Owens, Anjali, Wojakowski, Wojciech, Jensen, Morten K., Ho, Carolyn Y., Olivotto, Iacopo   +40 more
core   +1 more source

Hypertrophic Obstructive Cardiomyopathy

, 2020
Hypertrophic cardiomyopathy is a genetic cardiac disorder caused by a missense mutation in 1 of at least 10 genes that encode the proteins of the cardiac sarcomere.
Matthews, Sch Med On, Downloaded
core   +1 more source